ISSN: 1462-0324

Journal Home

Journal Guideline

Rheumatology Q1 Unclaimed

Oxford University Press United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Rheumatology is a journal indexed in SJR in Rheumatology and Pharmacology (medical) with an H index of 166. It has a price of 2500 €. It has an SJR impact factor of 1,897 and it has a best quartile of Q1. It is published in English.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Pharmacology (medical) (Q1) Rheumatology (Q1)

Price

2500 €

Gold OA

-

Green OA

0 €

Non OA

Metrics

1,897

SJR Impact factor

166

H Index

458

Total Docs (Last Year)

1179

Total Docs (3 years)

11596

Total Refs

4201

Total Cites (3 years)

865

Citable Docs (3 years)

4,85

Cites/Doc (2 years)

25,32

Ref/Doc

Aims and Scope

Other journals with similar parameters

Annals of the Rheumatic Diseases Q1
Arthritis and Rheumatology Q1
Nature Reviews Rheumatology Q1
Arthritis Care and Research Q1
Journal of Scleroderma and Related Disorders Q1

Best articles

A case of rheumatoid vasculitis involving the gastrointestinal tract in early disease

A comparative quantitative morphometric study of cell apoptosis in synovial membranes in psoriatic, reactive and rheumatoid arthritis.

A pilot study of cutaneous oxygenation and perfusion in systemic sclerosis-related digital calcinosis

A strong heritability of psoriatic arthritis over four generations--the Reykjavik Psoriatic Arthritis Study

Allergic pancytopenia to trimethoprim-sulphamethoxazole for Pneumocystis carinii pneumonia following methotrexate treatment for rheumatoid arthritis.

An embarrassment of pain perceptions? Towards an understanding of and explanation for the clinical presentation of CRPS type 1

An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases

Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial

Anti-neutrophil cytoplasmic autoantibodies in leprosy

ANTI-PROTEUS ANTIBODIES IN RHEUMATOID ARTHRITIS SAME-SEXED SIBSHIPS

ANTIGEN-PRESENTING CELLS BUT NOT LYMPHOCYTES IN THE JOINT MAY INDICATE THE CAUSE OF REACTIVE ARTHRITIS

ANTIRIBOSOMAL P PROTEIN ANTIBODIES IN DIFFERENT POPULATIONS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

SHOW MORE ARTICLES

Art and history: a large research avenue for rheumatologists

Arthritis as presenting manifestation of pure neuritic leprosy--a rheumatologist's dilemma

Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab

Assessment of endothelial function in complex regional pain syndrome type I using iontophoresis and laser Doppler imaging

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials

Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus

Cardiac and renal protective effects of urate-lowering therapy

Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases

Characterizing infection in anti-neutrophil cytoplasmic antibody-associated vasculitis: results from a longitudinal, matched-cohort data linkage study

Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response

Chemokine saliva levels in patients with primary Sjogren's syndrome, associated Sjogren's syndrome, pre-clinical Sjogren's syndrome and systemic autoimmune diseases

Clinically amyopathic dermatomyositis with anti-transcriptional intermediary factor 1- gamma autoantibody positivity

Comments

No comments ... Be the first to comment!

Publication speed

Review quality

Edition and editorial team

Paper Link

Attach one of your papers. We need to confirm that you have had a relation with this journal in order to review its service.